The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 February 2026•

1 min read

Anteris Technologies Secures $320M and FDA Approval for Heart Valve Trials

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Key Facts

1The company initiated the global pivotal PARADIGM Trial and received FDA IDE approval to start trials in the United States.

Anteris Technologies Global Corp. (AVR) has reported its full-year 2025 financial results alongside significant corporate milestones. The company successfully initiated its global pivotal PARADIGM Trial after receiving IDE approval from the U.S. FDA to commence trials in the United States. Clinical data for the DurAVR® THV system demonstrated favorable outcomes for aortic stenosis patients at both 30-day and one-year intervals. Strengthening its balance sheet, Anteris completed capital raises totaling $320 million in early 2026, featuring a strategic investment from Medtronic. These developments mark a critical transition for the company toward the global commercialization of its proprietary heart valve technology.